Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acalabrutinib in Combination With BR or VR in Mantle Cell Lymphoma
NCT02717624Phase 1Active, not recruiting
- Sponsor
- Acerta Pharma
- Start
- Apr 2016
- Primary completion
- Jun 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of acalabrutinib in mantle cell lymphoma (MCL) (3 arms), sponsored by Acerta Pharma. Primary endpoint: Number of Participants with Treatment Emergent Adverse Events. Started Apr 2016; status: active, not recruiting.
02
Drugs
acalabrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02717624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02717624.